"We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million," said Ben Albert, CEO of Health Catalyst "In 2026, we are focused on the future and on positioning Health Catalyst for long‑term success. As I continue to assess the business, I see both meaningful opportunities and clear areas where we must improve. I am confident in the strengths that continue to differentiate this company. Our mission, our people, and our core capabilities, grounded in thousands of improvement projects and billions of dollars in validated impact, provide a solid foundation for delivering meaningful value to our clients and shareholders. My priority is to build on these strengths, address our challenges with clarity and discipline, and move the company forward with a renewed sense of focus and execution."
Financial Highlights for the Three and Twelve Months Ended December 31, 2025
Key Financial Measures
Three Months EndedDecember 31,
Year over Year Change
Twelve Months EndedDecember 31,
Year over Year Change
2025
2024
2025
2024
GAAP Financial Measures:
(in thousands, except percentages)
(in thousands, except percentages)
Total revenue
$
74,679
$
79,606
(6
)%
$
311,136
$
306,584
1
%
Gross profit
$
31,385
$
28,618
10
%
$
120,356
$
114,503
5
%
Gross margin
42.0
%
35.9
%
38.7
%
37.3
%
Net loss
$
(91,025
)
$
(20,673
)
(340
)%
$
(177,974
)
$
(69,502
)
(156
)%
Non-GAAP Financial Measures:(1)
Adjusted Gross Profit
$
39,962
$
37,121
8
%
$
159,107
$
149,533
6
%
Adjusted Gross Margin
53.5
%
46.6
%
51.1
%
48.8
%
Adjusted EBITDA
$
13,786
$
7,911
74
%
$
41,408
$
26,105
59
%
________________________(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.
Other Key Metrics
As of December 31,
2025
2024
Platform Clients(1)*
162
130
Year Ended December 31,
2025
2024
Dollar-based Retention Rate (Tech + TEMS)(2)*
93
%
102
%
__________________ (1) At the beginning of 2025, we updated the name and definition of this key metric. Platform Clients are defined as: (i) all Platform Clients as of December 31, 2024 under our historical definition (i.e., these clients will be included in our Platform Client count until they cease to have an active subscription as of the end of the period), and (ii) as of January 1, 2025, any technology client that signs contracts with at least $100,000 of incremental total annual recurring revenue (ARR) and non-recurring revenue in a given calendar year, inclusive of clients that come through acquisition if we first begin recognizing revenue for the client post-acquisition and that total ARR and non-recurring revenue exceeds $100,000 in that calendar year, so long as such client maintains an active subscription as of the end of the period. Once a client is designated as a Platform Client, it will continue to be a Platform Client unless it is no longer a client with an active subscription as of the end of the period. Please see our Annual Report on Form 10-K for the year ended December 31, 2025 expected to be filed with the SEC on or about March 12, 2026 for additional information.(2) Dollar-based Retention Rate (Tech + TEMS) is calculated as of a period end by starting with the sum of the technology ARR and Tech-Enabled Managed Services (TEMS) ARR from our Platform Clients as of the date 12 months prior to such period end (this calculation excludes professional services ARR and non-recurring revenue), calculating the sum of the ARR from these same clients as of the current period end (which includes any upsells and also reflects contraction or attrition over the trailing twelve months but excludes revenue from new Platform Clients added in the current period who were not clients at the beginning of such period; this current period ARR may include acquired ARR from clients that overlap with the Platform Clients in a given calendar year), and then dividing the current period ARR by the prior period ARR. Please see our Annual Report on Form 10-K for the year ended December 31, 2025 expected to be filed with the SEC on or about March 12, 2026 for additional information.* We anticipate sunsetting our reporting of this metric for 2026 and future years, and we anticipate providing new 2026 growth metrics in lieu of this metric in the future.
Financial Outlook
Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.
For the first quarter of 2026, we expect:
Total revenue between $68 and $70 million, and
Adjusted EBITDA between $7 and $8 million
We have not provided forward-looking guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and therefore have not reconciled guidance for Adjusted EBITDA to net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted.
We are not providing forward-looking guidance for the full year of 2026 at this time due to an ongoing internal strategic and operational review in connection with our CEO transition.
Quarterly Conference Call Details
We will host a conference call to review the results today, Thursday, March 12, 2026, at 5:00 p.m. E.T. The conference call can be accessed by dialing (800) 343-5172 for U.S. participants, or (203) 518-9856 for international participants, and referencing conference ID "HCATQ425." A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Health Catalyst
Health Catalyst (NASDAQ:HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,200 organizations worldwide rely on Health Catalyst's offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.
Available Information
Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including our website (https://www.healthcatalyst.com/), our investor relations website (https://ir.healthcatalyst.com/), press releases, SEC filings, public conference calls, and social media, including our and our CEO's social media accounts such as LinkedIn (https://www.linkedin.com/in/ben-albert-0a763b1/ and https://www.linkedin.com/company/healthcatalyst/), in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, our growth strategies, our strategic priorities, and our financial outlook for Q1 2026. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners, clients reducing or eliminating their spend with us, client churn or down-selling in connection with the migration to Ignite or otherwise; (v) fluctuations in our project-based, non-recurring revenue, (vi) macroeconomic challenges (including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto), natural disasters or any new public health crises, and regional or global conflicts (including the conflicts in the Middle East); and (vii) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 that was filed with the SEC on November 10, 2025 and the Annual Report on Form 10-K for the year ended December 31, 2025 expected to be filed with the SEC on or about March 12, 2026. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.
Consolidated Balance Sheets(in thousands, except share and per share data)
As of December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
50,814
$
249,645
Short-term investments
44,918
142,355
Accounts receivable, net
59,128
57,182
Prepaid expenses and other assets
14,447
16,468
Total current assets
169,307
465,650
Property and equipment, net
33,838
29,394
Intangible assets, net
77,678
86,052
Operating lease right-of-use assets
6,640
12,058
Goodwill
209,073
259,759
Other assets
6,107
6,016
Total assets
$
502,643
$
858,929
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$
9,363
$
11,433
Accrued liabilities
18,697
26,340
Deferred revenue
56,107
53,281
Operating lease liabilities
3,779
3,614
Current portion of long-term debt
1,627
231,182
Total current liabilities
89,573
325,850
Long-term debt, net of current portion
151,624
151,178
Deferred revenue, net of current portion
410
249
Operating lease liabilities, net of current portion
14,208
16,291
Other liabilities
798
154
Total liabilities
256,863
493,722
Stockholders' equity:
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024
—
—
Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of December 31, 2025 and 2024; 72,027,332 and 64,043,799 shares issued and outstanding as of December 31, 2025 and 2024, respectively
1,608,840
1,552,714
Accumulated deficit
(1,364,646
)
(1,186,672
)
Accumulated other comprehensive income (loss)
1,586
(835
)
Total stockholders' equity
245,780
365,207
Total liabilities and stockholders' equity
$
502,643
$
858,929
Consolidated Statements of Operations(in thousands, except per share data, unaudited)
Three Months EndedDecember 31,
Twelve Months EndedDecember 31,
2025
2024
2025
2024
Revenue:
Technology
$
51,868
$
51,598
$
208,277
$
194,852
Professional services
22,811
28,008
102,859
111,732
Total revenue
74,679
79,606
311,136
306,584
Cost of revenue, excluding depreciation and amortization:
Technology(1)(2)(3)
16,621
18,821
69,741
67,812
Professional services(1)(2)(3)
18,675
26,094
89,720
97,993
Total cost of revenue, excluding depreciation and amortization
35,296
44,915
159,461
165,805
Operating expenses:
Sales and marketing(1)(2)(3)
10,172
11,242
52,477
54,387
Research and development(1)(2)(3)
9,911
15,002
49,770
57,950
General and administrative(1)(2)(3)(4)
11,044
15,681
49,559
56,817
Depreciation and amortization
12,882
10,266
50,500
41,431
Impairment of goodwill and intangible assets
81,454
—
110,223
—
Total operating expenses
125,463
52,191
312,529
210,585
Loss from operations
(86,080
)
(17,500
)
(160,854
)
(69,806
)
Interest and other expense, net
(4,566
)
(2,548
)
(16,404
)
637
Loss before income taxes
(90,646
)
(20,048
)
(177,258
)
(69,169
)
Income tax provision
379
625
716
333
Net loss
$
(91,025
)
$
(20,673
)
$
(177,974
)
$
(69,502
)
Net loss per share, basic and diluted
$
(1.28
)
$
(0.33
)
$
(2.55
)
$
(1.15
)
Weighted-average shares outstanding used in calculating net loss per share, basic and diluted
70,998
62,377
69,896
60,185
_______________(1) Includes stock-based compensation expense as follows:
Three Months Ended December 31,
Twelve Months Ended December 31,
2025
2024
2025
